Millions of adults undergoing breast and colorectal cancer screening are eligible for lung cancer screening, but do not get screened
Menée aux Etats-Unis, cette étude évalue le taux d'éligibilité et le taux de participation au dépistage du cancer du poumon chez les personnes adultes ayant bénéficié d'un dépistage du cancer du sein ou du cancer colorectal
Introduction : To evaluate lung cancer screening eligibility and use among U.S. adults undergoing breast and colorectal cancer screening.
Methods : Participants in the 2024 Behavioral Risk Factor Surveillance System were identified. Females aged 50 to 74 up-to-date on screening mammography were included in the breast cancer screening cohort. Males and females aged 50 to 75 up-to-date on screening colonoscopy or sigmoidoscopy were included in the colorectal cancer screening cohort. In each cohort, lung cancer screening eligibility (according to the 2021 U.S. Preventive Services Task Force criteria) and use were evaluated. BRFSS survey weights were applied to obtain national estimates of screening eligibility and use.
Results : In the breast cancer screening cohort, 9.9% (weighted number 3.6 million) were eligible for lung cancer screening. In the colorectal cancer screening cohort, 11.8% (weighted number: 7.4 million) were eligible for lung cancer screening. Together, 8.4 million adults up-to-date on breast or colorectal cancer screening were eligible for lung cancer screening. However, lung cancer screening use among eligible adults in the breast and colorectal cancer screening cohorts was only 28.7% and 27.7%, respectively. If all eligible adults up-to-date on breast or colorectal cancer screening underwent lung cancer screening in 2024, overall lung cancer screening uptake in the U.S. would increase from 22.7% to 70.5%.
Conclusion : In this national analysis, there were 8.4 million adults up-to-date on breast or colorectal cancer screening who were eligible for lung cancer screening; if these adults had undergone lung cancer screening in 2024, lung cancer screening uptake in the U.S. would increase 3-fold to 71%.
Journal of the National Cancer Institute , résumé, 2026